J Cell Biochem 88(2):234237
TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief Eli Lilly and Company has announced positive topline results from the phase 3 TRIUMPH-4 clinical trial assessing the safety and efficacy of the 2 largest investigational doses of retatrutide in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity.1 According to a December 11, 2025, release from the Company, both the 9 mg and 12 mg doses of the first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist met all primary and key secondary endpoints, delivering significant weight loss and improvements in pain and physical function at 68 weeks using both the efficacy and treatment-regimen estimands.1 "People with obesity and knee osteoarthritis often live with pain and restricted mobility, and may eventually require total joint replacement," said Kenneth Custer , PhD, executive vice president and president, Lilly Cardiometabolic Health.1 "We are encouraged by the results of TRIUMPH-4, which highlight the powerful effect of retatrutide, a first-in-class triple agonist, on body weight, pain and physical function
However, artificial sweeteners may actually contribute to the development or worsening of not only T2D but also obesity and cardiovascular disease
People who have a history or family history of a rare thyroid cancer (medullary thyroid carcinoma) should not use this medication, says Gudzune
What happens if I shake the Retatrutide vial after adding water
A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients
